tracked. This update does not introduce a new thesis; it gives the existing one more structure. FY2025 revenue rose to USD 124,157, gross profit turned positive at USD 102,911, gross margin reached 82.9%, and the filed 10-K shows that 99.4% of FY2025 revenue came from AI Nose-related programs. That matters because the near-term commercial story is now being carried much more clearly by industrial smelltech, not by broad platform optionality alone.<\/p>\n\n\n\n
The more important change is on execution visibility. Management now points to around 200 front-end wafer-fab systems targeted for technical validation, around 1,400 systems under the previously disclosed three-year USD 2.1 million ASE framework, a disclosed ~USD 350k deposit, and a stated Q2 2026 completion target for that rollout phase. The 10-K also adds a contracted minimum commitment of 600 AI Nose units with a semiconductor engineering and systems-integration partner, while ~USD 2.82 million of financing from an ASE group company strengthens liquidity.<\/p>\n\n\n\n
The correct investor read remains disciplined: Ainos is moving from proof-of-concept toward early commercial execution, but broader scale-up still depends on validation results and contractual conversion. What has improved is not certainty of full rollout, but the number of visible checkpoints the market can now track.<\/p>\n\n\n\n